top
Please input keywords
OK
Database
ニュース&PR
お問い合わせ
JP
CN
EN
KR
About us
会社情報
私たちの歩み
管理スタッフ
企業文化
社会的責任
共に働く
Antibody therapeutics R&D
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
動物・細胞モデル
Pharmacology service
ゲノム編集
研究提携
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
研究提携
研究提携
オープンイノベーションによる革新的な新薬の研究開発
Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.
Collaboration Models
Antibody Out-licensing
Antibody Co-Development
Antibody Transfer
Technology Platform Out-licensing
Various drug modalities
Monoclonal Antibody
Bispecific Antibody
Bispecific ADC
Nanobodie
TCRm Antibody
Cell Therapy
Established partnerships
50
50 therapeutic antibody co-development/out-licensing/transfer agreements
42
42 target-nominated RenMice licensing projects
5
5 pipeline-based co-development
Disclosed Partners
Worldwide antibody assets or platform partners include Merck KGaA, Janssen, Xencor, ADC Therapeutics, RemeGen and BeiGene.
Contact us for antibody assets and platforms partnership opportunities at BD-Licensing@biocytogen.com.